Glyconics Ltd

Product: 
Life Sciences
Status: 
Closed
Sector: 
Diagnostcis
Aim of funding: 
Seed
HMRC Advance Assurance received: 
Yes

Glyconics Ltd

Description: 

Glyconics Ltd is an innovative diagnostics company which has developed a novel approach to the diagnosis and monitoring of chronic and acute diseases including respiratory disease.  The new device uses fourier transform infrared spectroscopy (FITR) to analyse sputum (saliva) samples for specific biomarkers, characteristic of chronic obstructive pulmonary disease (COPD).

The team at Glyconics has been working to develop the new hand-held miniaturised device to be able to effectively diagnose and predict the exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in patients at the point of care.  The Company’s aim is to optimise the hand-held, miniaturised FTIR device for easy detection of disease monitoring by healthcare workers at the point-of-care. The technology meets a clear medical need in the diagnosis, monitoring and clinical management of acute and chronic diseases.

Opportunity: 

In the UK in 2012, 29,776 people died from COPD, 2,719 were aged 15–64; 27,056 were aged 65 and above making it a predominately an age-related disease. Along with lung cancer and pneumonia, COPD is one of the three leading contributors to respiratory mortality in developed countries. (1.)

Examples of chronic COPD conditions include emphysema, chronic bronchitis and severe asthma.According to research carried out by Rightcare, NHS and ERPHO estimated that around 835,000 people in England are currently diagnosed with COPD and a further 2.2 million are undiagnosed (1).

The cost of treating COPD cost the NHS an estimated £1.2 billion per annum in 2010 (2.). COPD is the fifth biggest killer disease in the UK, killing approximately 25,000 people a year in England (3).     

Glyconics Ltd plans to offer direct sales of the miniaturised IR device via the traditional medical distributor route for a retail price of £750 with the single use sputum disposable test selling at approximately £5 each. It is envisaged that the bulk of future recurring revenues will come from the repeat sale of the single use disposable test. 

[1] https://statistics.blf.org.uk/copd

[2] http://www.rightcare.nhs.uk/index.php/atlas/respiratorydisease/

[3] http://intelesant.com/copd-factsheet-june-2015/

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.